A comprehensive study that examined pleural mesothelioma patients aged 65 and older has revealed what any of those patients could easily confirm: treatment of the rare, asbestos-related disease creates staggering healthcare costs and resource utilization, with the average total healthcare expenses reaching $11,432 per patient per month during treatment.
Category: Uncategorized
Supreme Court Denies Volkswagen’s Appeal in California Mesothelioma Case
This week, the U.S. Supreme Court declined to hear a challenge from Volkswagen AG to California’s jurisdiction in a mesothelioma lawsuit. The decision by the nation’s highest court allows the case brought by the family of deceased auto mechanic Raul Hernandez to proceed against the German automaker.
Asbestos Tile Manufacturer Fails in Attempt to Evade Mesothelioma Liability
Mesothelioma victim Jon Widercrantz filed a personal injury lawsuit against multiple companies whose asbestos he blames for his illness, including asbestos tile manufacturer American Biltrite Inc. (ABI). The company filed a petition to have the case against it dismissed, asserting that asbestos released from its tiles would not have been distinguishable from ambient air exposure
Federal Charges Filed after Waukegan Hospital Demolition Creates Mesothelioma Risk
Federal criminal charges have been filed after an asbestos demolition company’s actions exposed workers and the public to the risk of mesothelioma. The 24-count indictment filed by the U.S. Attorney’s Office accuses Carl Fioravanti, president of Alliance Environmental Control, Inc., of making false statements during the demolition of the former Lakes Behavioral Hospital in Waukegan,
40.6% of all EU Occupational Cancer Victims Have Mesothelioma
A report published by the European Union’s statistical office demonstrates that mesothelioma accounted for 16,469 of the 40,538 occupational cancer cases officially recognized in the European Union between 2013 and 2023. The report issued by Eurostat shows that despite steps taken to minimize asbestos exposure, the rare disease represents 40.6 percent of all diagnosed work-related
Mesothelioma Incidence Rose from 1999 to 2011, Then Declined Through 2020
A group of international researchers has published a noteworthy article concluding that the number of U.S. mesothelioma cases significantly increased from 1999 through 2011, then gradually declined through 2020. The scientists noted the higher incidence of the asbestos-related disease among individuals aged 75 years and older, men, and White populations. The group concludes that enhanced
Mesothelioma Incidence Rose from 1999 to 2011, Then Declined Through 2020
A group of international researchers has published a noteworthy article concluding that the number of U.S. mesothelioma cases significantly increased from 1999 through 2011, then gradually declined through 2020. The scientists noted the higher incidence of the asbestos-related disease among individuals aged 75 years and older, men, and White populations. The group concludes that enhanced
Family Can Continue Mesothelioma Claim Against Turbine Manufacturer
The family of mesothelioma victim Michael P. Dandry Jr. won an early legal round in its attempt to hold turbine manufacturer Paramount Global responsible for their loved one’s death. The company had filed a motion to have the occupational exposure case against it dismissed, but a U.S. District Court Judge ruled that a reasonable jury
Mesothelioma Researcher Defends Article Against Johnson & Johnson Libel Claims
Respected mesothelioma researcher Dr. Jacqueline Moline was in court last week, defending herself against claims of trade libel lodged by Johnson & Johnson’s bankrupt talc subsidiary Pecos River Talc LLC. The company’s previous claim against her had been dismissed based on First Amendment protections, but its attorneys asserted they’d found new information and refiled its
Researchers Advance Mesothelioma Treatments Using Patient Fluid and Tissue Samples
Researchers in China are creating miniaturized versions of mesothelioma tumors to create personalized treatment models for this rare and aggressive cancer. Using malignant ascites, pleural effusions, fine-needle biopsies, and surgical tissues to create patient-derived organoids (PDOs), they hope to improve the poor outcomes and therapy resistance typical of the disease.